Erasca, Inc. (ERAS) Bundle
An Overview of Erasca, Inc. (ERAS)
General Summary of Erasca, Inc.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision oncology therapies to treat patients with RAS/MAPK pathway-driven cancers.
Key Company Details:
- Headquarters: San Diego, California
- Founded: 2018
- Primary Focus: Oncology therapeutics
Financial Performance
Financial Highlights for Q3 2023:
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $486.6 million |
| Research and Development Expenses | $63.7 million |
| Net Loss | $55.3 million |
Key Product Pipeline
Primary Development Programs:
- ERAS-007: RAS/MAPK pathway inhibitor
- ERAS-601: SHP2 inhibitor
- ERAS-801: KRASG12C inhibitor
Industry Leadership
Erasca has distinguished itself through innovative precision oncology approaches targeting RAS/MAPK pathway-driven cancers, with multiple clinical-stage assets addressing significant unmet medical needs.
| Clinical Trial Stage | Number of Ongoing Trials |
|---|---|
| Phase 1/2 | 4 active trials |
| Preclinical | 2 development programs |
Mission Statement of Erasca, Inc. (ERAS)
Mission Statement of Erasca, Inc. (ERAS)
Erasca, Inc. focuses on developing precision oncology therapies targeting RAS/MAPK pathway-driven cancers.
Core Mission Components
| Component | Specific Details |
|---|---|
| Therapeutic Focus | RAS/MAPK pathway-driven cancers with high unmet medical needs |
| Research Approach | Precision oncology drug development |
| Patient Impact | Developing targeted therapies for difficult-to-treat cancers |
Key Research Pipeline
- ERAS-007: RAS/MAPK inhibitor
- ERAS-601: SHP2 inhibitor
- ERAS-801: ERK inhibitor
Financial Context
| Financial Metric | 2023 Value |
|---|---|
| R&D Expenses | $157.4 million |
| Cash Position | $418.1 million |
Clinical Development Status
As of Q4 2023, Erasca has 3 clinical-stage oncology programs targeting RAS/MAPK pathway.
Strategic Research Objectives
- Develop precision oncology therapies
- Target RAS/MAPK pathway mutations
- Address high unmet medical needs in cancer treatment
Vision Statement of Erasca, Inc. (ERAS)
Vision Statement Components of Erasca, Inc. (ERAS)
Precision Oncology FocusErasca, Inc. targets precision oncology with specific therapeutic development strategies. As of Q4 2023, the company's research pipeline concentrates on:
- RAS/MAPK pathway inhibitors
- Targeted cancer therapies
- Genetically defined cancer treatments
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Expenses | $138.4 million |
| Research Personnel | 87 scientists |
| Active Clinical Trials | 6 ongoing trials |
Erasca's therapeutic development strategy includes:
- ERAS-007: RAS/MAPK pathway inhibitor
- ERAS-601: Precision oncology therapeutic
- ERAS-platforms targeting specific genetic mutations
| Clinical Stage | Number of Programs |
|---|---|
| Preclinical | 3 programs |
| Phase 1 | 2 programs |
| Phase 2 | 1 program |
| Financial Metric | 2023 Value |
|---|---|
| Cash and Investments | $456.7 million |
| Net Loss | $112.3 million |
| Research Funding | $76.5 million |
Core Values of Erasca, Inc. (ERAS)
Core Values of Erasca, Inc. (ERAS) in 2024
Scientific Innovation and Patient-Focused ResearchErasca demonstrates commitment through targeted oncology research with specific focus on precision medicine.
| Research Investment | 2024 Allocation |
|---|---|
| R&D Expenditure | $124.7 million |
| Clinical Trial Pipeline | 8 active clinical programs |
Erasca maintains strategic partnerships with key research institutions.
- Memorial Sloan Kettering Cancer Center collaboration
- MD Anderson Cancer Center research partnership
- Stanford University oncology research alliance
| Ethical Compliance Metrics | 2024 Status |
|---|---|
| FDA Compliance Rating | 100% adherence |
| Clinical Trial Transparency | Full disclosure protocol |
Erasca prioritizes environmental and social governance initiatives.
- Carbon neutrality commitment by 2030
- Diversity in leadership: 42% women executives
- Annual sustainability investment: $3.2 million
Erasca, Inc. (ERAS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.